Cited by 2,051Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record.

Cancer Immunotherapy

Couzin-Frankel, Jennifer·2013·Science

Open this paper in CoChat — free account

Abstract

This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.

Integrity signals

Registry

Crossref · 10.1126/science.342.6165.1432

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 801–900 of 1,000

Mechanisms regulating immune surveillance of cellular stress in cancer
Seelige, R., Searles, S. C., & Bui, J. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2597-7 · Cited by 32
“Indeed, the field of cancer immune therapy, heralded as a “Breakthrough of the Year” [33], critically relies on mobilizing anti-tumor immune effectors while diminishing the activity of pro-tumor inflammation.”
Background
Tumor immune cell clustering and its association with survival in African American women with ovarian cancer
Wilson, C. M., Soupir, A. C., Thapa, R., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009900 · Cited by 30
A comprehensive review on the use of traditional Chinese medicine for cancer treatment
Yadav, N., Deshmukh, R., & Mazumder, R. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100423 · Cited by 36
Current State of Pediatric Lung Transplantation
Hayes, D., Benden, C., Sweet, S. C., & Conrad, C. (2015) · Lung · doi:10.1007/s00408-015-9765-z · Cited by 30
“In the more recent era, different classes of therapies have emerged, such as monoclonal antibodies and T cell engineering, as two examples, which have proved promising and effective in cancer chemotherapy [77].”
Background
Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment
Hong, X., Wang, X., Wang, T., et al. (2018) · Medical Science Monitor · doi:10.12659/msm.910388 · Cited by 30
Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology
Signore, A., Lauri, C., Auletta, S., Anzola, L. K., Galli, F., Casali, M., Versari, A., & Glaudemans, A. W. J. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050681 · Cited by 30
“Cancer immunotherapy was in 2013 selected as “Breakthrough of the Year” by Science, as the editors concluded that long-sought efforts to unleash the immune system against tumours are paying off, but they also stated that researchers are largely clueless as to which patients do benefit and that biomarkers have to be id…”
Background
Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
Loosen, S. H., den Bosch, V. V., Gorgulho, J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071361 · Cited by 30
Transformable vesicles for cancer immunotherapy
Wang, S., Hu, X., Wei, W., & Ma, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113905 · Cited by 31
Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer
Qiu, X., Zhang, F.-F., Geng, F., Liu, C., Wang, Y., Xu, P., Lu, Z.-Z., Xie, Y., Wu, H., Chen, Y., et al. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.08.006 · Cited by 30
Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma
Qiu, X., Geng, F., Zhang, F.-F., Liu, C., Xu, P., Lu, Z.-Z., Xie, Y., Sun, B., Wu, H., Yu, B., et al. (2016) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2016.1269337 · Cited by 31
Hypothesis: Hypoxia induces de novo synthesis of NeuGc gangliosides in humans through CMAH domain substitute
Bousquet, P. A., Sandvik, J. A., Edin, N. F. J., & Krengel, U. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.183 · Cited by 31
“Cancer immunotherapy promises a revolution in cancer therapy, and was consequently selected by Science as Breakthrough of the year 2013 (Couzin-Frankel 2013).”
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
Linsley, P. S., & Long, S. A. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000488 · Cited by 30
Lymph-directed immunotherapy – Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer
Feeney, O. M., Gracia, G., Brundel, D. H. S., Trevaskis, N. L., Cao, E., Kaminskas, L. M., & Porter, C. J. H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.002 · Cited by 31
A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy
Peng, S., & Bao, Y. (2021) · Annals of Blood · doi:10.21037/aob-21-3 · Cited by 29
“Due to the demonstrated efficacy of several of these therapies, such as brake antibodies and genetically modified T cells, Science magazine deemed cancer immunotherapy the ‘Breakthrough of the Year’ in 2013 (2).”
Background
Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential
Liu, X.-H., Qi, L., Alolga, R. N., & Liu, Q. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.66834 · Cited by 29
Antigen targeting to dendritic cells: Still a place in future immunotherapy?
Stoitzner, P., Romani, N., Rademacher, C., Probst, H. C., & Mahnke, K. (2022) · European Journal of Immunology · doi:10.1002/eji.202149515 · Cited by 29
Recent advances in erythrocyte membrane-camouflaged nanoparticles for the delivery of anti-cancer therapeutics
Wang, S., Wang, Y., Jin, K., Zhang, B., Peng, S., Nayak, A. K., & Pang, Z. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2108786 · Cited by 31
Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives
Farooq, M. U., Lawrie, C. H., & Deng, N. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150356 · Cited by 30
Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity
Müller, P., Martin, K., Theurich, S., von Bergwelt‐Baildon, M., & Zippelius, A. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954460 · Cited by 29
“The field of cancer immunotherapy is moving forward at an accelerated pace and was honorably selected as Breakthrough of the Year in 2013 by the editors of Science.(1) Following many disappointments and decades long struggles to successfully implement cancer immunotherapy from the bench to the bedside the concerted ef…”
Background
New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT
Chang, X., Zang, X., & Xia, C.-Q. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.288 · Cited by 29
The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy
Ji, H., Xuan, Q., Yan, M., Liu, T., Nanding, A., & Zhang, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.8993 · Cited by 29
Treatment of advanced melanoma with laser immunotherapy and ipilimumab
Naylor, M. F., Zhou, F., Geister, B. V., et al. (2017) · Journal of Biophotonics · doi:10.1002/jbio.201600271 · Cited by 29
Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations
Wang, G. X., Guo, L. Q., Gainor, J. F., & Fintelmann, F. J. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.16.17770 · Cited by 29
Is adaptive therapy natural?
Thomas, F., Donnadieu, E., Charrière, G. M., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2007066 · Cited by 29
Advances in living cell-based anticancer therapeutics
Dong, H., Xu, X., Wang, L., & Mo, R. (2020) · Biomaterials Science · doi:10.1039/d0bm00036a · Cited by 29
Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC
Mahmoudian, R. A., Mozhgani, S., Abbaszadegan, M. R., Mokhlessi, L., Montazer, M., & Gholamin, M. (2021) · Journal of Molecular Histology · doi:10.1007/s10735-021-09971-3 · Cited by 29
The Impact of m1A Methylation Modification Patterns on Tumor Immune Microenvironment and Prognosis in Oral Squamous Cell Carcinoma
Gao, L., Chen, R., Sugimoto, M., Mizuta, M., Kishimoto, Y., & Omori, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910302 · Cited by 29
Programming Receptor Clustering with DNA Probabilistic Circuits for Enhanced Natural Killer Cell Recognition
Xiao, M., Lai, W., Yao, X., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202203800 · Cited by 29
Targeting CD47 as a Novel Immunotherapy for Breast Cancer
Chen, C., Wang, R., Chen, X., Hou, Y., & Jiang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924740 · Cited by 30
Nanovaccines for cancer immunotherapy: Current knowledge and future perspectives
Wu, Y., Zhang, Z., Wei, Y., Qian, Z., & Wei, X. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.108098 · Cited by 30
Calcium-deprivation-activated immune responses for solid tumor regression
Bao, Q., Fu, H., Guo, Y., Hu, P., & Shi, J. (2024) · Chem · doi:10.1016/j.chempr.2023.12.020 · Cited by 28
The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation
Pereboeva, L., Harkins, L. E., Wong, C. S., & Lamb, L. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1662-z · Cited by 32
Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure
Anderson, K., & Modiano, J. F. (2015) · Veterinary Sciences · doi:10.3390/vetsci2040363 · Cited by 30
Photonics immunotherapy — A novel strategy for cancer treatment
Zhou, F., Nordquist, R. E., & Chen, W. R. (2015) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545816300019 · Cited by 29
Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues
Bardo, P., Vieillard, V., Shekarian, T., Marabelle, A., Astier, A., & Paul, M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.008 · Cited by 28
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini
Kowalewski, D. J., Walz, J. S., Backert, L., Schuster, H., Kohlbacher, O., Weisel, K. C., Rittig, S. M., Kanz, L., Salih, H. R., Rammensee, H., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.14 · Cited by 26
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope
Morales‐Barrera, R., Suárez, C., de Castro, A. M. M., Racca, F., Valverde, C. M., Maldonado, X., Bastaros, J. M., Moróte, J., & Carles, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.018 · Cited by 26
Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate
Shi, J. D., Zhou, S., Kang, L., Hu, L., Chen, J., Duan, L., Song, Y., & Deng, Y. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0424-1 · Cited by 28
William Bradley Coley, MD, and the phenomenon of spontaneous regression
Vernon, L. F. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s163924 · Cited by 28
Integrating Small Animal Irradiators with Functional Imaging for Advanced Preclinical Radiotherapy Research
Ghita, M., Brown, K. H., Kelada, O. J., Graves, E. E., & Butterworth, K. T. (2019) · Cancers · doi:10.3390/cancers11020170 · Cited by 28
S quamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity
Turato, C., Scarpa, M., Kotsafti, A., Cappon, A., Quarta, S., Biasiolo, A., Cavallin, F., Trevellin, E., Guzzardo, V., Fassan, M., et al. (2019) · Cancer Science · doi:10.1111/cas.13986 · Cited by 27
Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer
Zhang, X., Chen, H., Li, G., Zhou, X., Shi, Y., Zou, F., Chen, Y., Gao, J., Yang, S., Wu, S., et al. (2019) · Journal of Cancer · doi:10.7150/jca.29705 · Cited by 29
Clinicopathological significance of CD47 expression in hepatocellular carcinoma
Kim, H., Bang, S., Jee, S., et al. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206611 · Cited by 28
Precision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 29
Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy
Li, Z., Shen, Q., Mao, Z., & Tan, C. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200270 · Cited by 29
Strategies for developing PD-1 inhibitors and future directions
Chen, W., Huang, Y., Pan, W., Xu, M., & Chen, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115113 · Cited by 28
Anion receptor-mediated multicomponent synergistic self-assembly of porphyrin for efficient phototherapy to elicit tumor immunotherapy
Wang, K., Chen, J., Lin, L., Yan, N., Yang, W., Cai, K., Tian, H., & Chen, X. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101579 · Cited by 30
T cell-responsive macroporous hydrogels for in situ T cell expansion and enhanced antitumor efficacy
Bhatta, R., Han, J., Liu, Y., Yang, B., & Wang, H. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121972 · Cited by 30
A PDA‐Functionalized 3D Lung Scaffold Bioplatform to Construct Complicated Breast Tumor Microenvironment for Anticancer Drug Screening and Immunotherapy
Zhang, W., Chen, Y. X., Li, M., Cao, S., Wang, N., Zhang, Y., & Wang, Y.-T. (2023) · Advanced Science · doi:10.1002/advs.202302855 · Cited by 25
Engineered Microglia‐Exosomes Coated Highly Twisting AIE Photothermal Agents to Efficiently Cross Blood‐Brain‐Barrier for Mild Photothermal‐Immune Checkpoint Blockade Therapy in Glioblastoma
Lin, X., Sun, Z., Huang, S., Liu, C., Peng, J., Li, Y., Xiong, Y., Gao, H., Chen, J., Qi, J., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202310237 · Cited by 28
Toll‐like receptors 2, 4, and 9 in primary, metastasized, and recurrent oral tongue squamous cell carcinomas
Mäkinen, L. K., Ahmed, A., Hagström, J., Lehtonen, S. H., Mäkitie, A. A., Salo, T. A., Haglund, C. H., & Atula, T. S. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12373 · Cited by 28
Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance
Gong, N., Zhang, Y., Zhang, Z., Li, X., & Liang, X. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201806087 · Cited by 29
Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators
Hua, S., Chen, F., Wang, X., Wang, Y., & Gou, S. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.02.004 · Cited by 28
A comprehensive review of stroke-related signaling pathways and treatment in western medicine and traditional Chinese medicine
Chen, B., & Jin, W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1200061 · Cited by 29
Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer
Skaličková, M., Vanova, K. H., Uher, O., Fialová, J. L., Petrláková, K., Masařík, M., Kejík, Z., Pavel Martasek, E., Pacák, K., & Jakubek, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479483 · Cited by 28
“…scienti ﬁ c advances, hallmarks of cancer (59) and the neoadjuvant approach were introduced (60), immunotherapy was named the Breakthrough of 2013 (61), and itRECIST criteria, i.e., recommendations for the assessment of intratumoral immunotherapy clinical trials, was proposed (in lorange) ( 62)…”
Palmitoylation prevents B7-H4 lysosomal degradation sustaining tumor immune evasion
Yan, Y., Yu, J., Wang, W., Xu, Y., Tison, K., Xiao, R., Grove, S., Wei, S., Vatan, L., Wicha, M. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58552-5 · Cited by 33
Nanobodies and their derivatives: pioneering the future of cancer immunotherapy
Li, H., Zhou, Q., Cao, N., Hu, C., Wang, J., He, Y. T., Jiang, S., Li, Q., Chen, M., Li, G., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02270-4 · Cited by 32
Perspectives for immunotherapy in glioblastoma treatment
Finocchiaro, G., & Pellegatta, S. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000135 · Cited by 27
Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles
Hutzler, S., Erbar, S., Jabulowsky, R. A., Hanauer, J. R. H., Schnotz, J. H., Beißert, T., Bodmer, B. S., Eberle, R., Böller, K., Klamp, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16928-8 · Cited by 29
Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade
Hu, Y., Lın, L., Chen, J., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c12734 · Cited by 27
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
Heitmann, J. S., Pflügler, M., Jung, G., & Salih, H. R. (2021) · Cancers · doi:10.3390/cancers13030549 · Cited by 29
“Particularly in melanoma and lung cancer with metastatic disease, CI can induce long-lasting remissions even in patients with high tumor burden [9], but durable responses are so far achieved in a minor subset of patients only [10–16], and treatment is associated with considerable side effects due to the induction of a…”
Background
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
Ludovini, V., Bianconi, F., Siggillino, A., Vannucci, J., Baglivo, S., Berti, V., Tofanetti, F. R., Reda, M. S., Bellezza, G., Mandarano, M., et al. (2021) · Genes · doi:10.3390/genes12020273 · Cited by 28
Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation
Li, C. M., & Chen, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.664305 · Cited by 29
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
Liu, H., Wang, R., An, D., Liu, H., Ye, F., Li, B., Zhang, J., Liu, P., Zhang, X., Yao, S., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108307 · Cited by 28
Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies
Cilibrasi, C., Papanastasopoulos, P., Samuels, M. E., & Giamas, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112015 · Cited by 28
Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
Alkholifi, F. K., & Alsaffar, R. M. (2022) · Medicina · doi:10.3390/medicina58111572 · Cited by 28
RETRACTED: Precision Medicine on the Effects of Microbiota on Head–Neck Diseases and Biomarkers Diagnosis
Inchingolo, A. M., Malcangi, G., Piras, F., Palmieri, G., Settanni, V., Riccaldo, L., Morolla, R., Buongiorno, S., de Ruvo, E., Inchingolo, A. D., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060933 · Cited by 30
Retracted
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
Volpe, A., Man, F., Lim, L., et al. (2018) · Journal of Visualized Experiments · doi:10.3791/57088 · Cited by 27
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement, A., Meng, Y., Cooper, M., et al. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1547303 · Cited by 27
Remodeling of the Tumor Microenvironment by a Chemokine/Anti-PD-L1 Nanobody Fusion Protein
Fang, T., Li, R., Li, Z., Cho, J., Guzman, J. S., Kamm, R. D., & Ploegh, H. L. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00078 · Cited by 27
In Situ Sprayed Exosome-Cross-Linked Gel as Artificial Lymph Nodes for Postoperative Glioblastoma Immunotherapy
Bao, P., Gu, H.-Y., Jiang, Y.-C., Wang, J., Wu, M., Yu, A., Zhong, Z., & Zhang, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c02425 · Cited by 28
Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
Yelton, C. J., & Ray, S. K. (2018) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2018.58 · Cited by 26
“However, active research in this area into how the tumor evades the immune system has led to novel therapies in the fight against these pathologies, with cancer immunotherapy even being heralded as the “breakthrough of the year” roughly five years ago[8].”
Background
In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1
Zhai, W., Zhou, X., Du, J., & Gao, Y. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.051 · Cited by 27
Pristine large pore benzene-bridged mesoporous organosilica nanoparticles as an adjuvant and co-delivery platform for eliciting potent antitumor immunity
Jambhrunkar, M., Yang, Y., Yu, M., et al. (2020) · Materials Today Advances · doi:10.1016/j.mtadv.2020.100069 · Cited by 26
Microfluidic Tumor Vasculature Model to Recapitulate an Endothelial Immune Barrier Expressing FasL
Kim, S., Park, J., Kim, J., & Jeon, J. S. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01542 · Cited by 27
Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors
Abken, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.165 · Cited by 27
Genetic Engineering of Dendritic Cells Using Partially Zwitterionic Dendrimer-Entrapped Gold Nanoparticles Boosts Efficient Tumor Immunotherapy
Ouyang, Z., Gao, Y., Yang, R., Shen, M., & Shi, X. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.1c01571 · Cited by 26
Tumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 27
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
Drouin, M., Coronilla, J. S., Gauttier, V., Berangere, E., Teppaz, G., Pengam, S., Mary, C., Desselle, A., Thépenier, V., Wilhelm, E., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo7621 · Cited by 26
Targeting the Alternatively Spliced Soluble Isoform of CTLA-4: Prospects for Immunotherapy?
Ward, F. J., Dahal, L. N., Khanolkar, R. C., Shankar, S. P., & Barker, R. N. (2014) · Immunotherapy · doi:10.2217/imt.14.73 · Cited by 27
Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development
Sim, G. C., Chacon, J. A., Haymaker, C., Ritthipichai, K., Singh, M. P., Hwu, P., & Radvanyi, L. G. (2014) · BioDrugs · doi:10.1007/s40259-014-0097-y · Cited by 27
Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia
Lee, J. Y., Park, S., Min, W.-S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.027 · Cited by 26
Nanoantagonists with nanophase-segregated surfaces for improved cancer immunotherapy
Ma, Y., Qiao, S., Wang, Y., Lin, Y., An, H., Wu, X., Wang, L., & Wang, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.048 · Cited by 26
Concordance measure and discriminatory accuracy in transformation cure models
Zhang, Y., & Shao, Y. (2017) · Biostatistics · doi:10.1093/biostatistics/kxx016 · Cited by 26
A Self‐Delivery Chimeric Peptide for Photodynamic Therapy Amplified Immunotherapy
Cheng, H. B., Fan, G., Fan, J., Zheng, R., Zhao, L., Yuan, P., Zhao, X., Yu, X., & Li, S. (2018) · Macromolecular Bioscience · doi:10.1002/mabi.201800410 · Cited by 26
Peptide therapeutics and assemblies for cancer immunotherapy
Li, M., Zhao, X., Dai, J., & Yu, Z. (2019) · Science China Materials · doi:10.1007/s40843-019-9451-7 · Cited by 28
Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators
Palermo, E., Acchioni, C., Carlo, D. D., et al. (2019) · Journal of Virology · doi:10.1128/jvi.01194-19 · Cited by 26
Immunological Consequences of Nanoparticle‐Mediated Antitumor Photoimmunotherapy
Hameed, S., Mo, S., Mustafa, G., Bajwa, S. Z., Khan, W. S., & Dai, Z. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900101 · Cited by 26
Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL
Zhou, W., Miao, J., Cheng, Z., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.08.009 · Cited by 25
“Chimeric antigen receptor-modified T (CAR-T) cell therapy has been demonstrated as a promising treatment for malignant diseases in recent years.(7,8) In clinical studies, CD19 CAR-T cells have exhibited impressive efficacy with a complete response (CR) rate of R90% against B cell acute lymphoblastic leukemia (B-ALL)(9…”
Background
Nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy
Xie, X., Zhang, J., Wang, Y., Shi, W., Tang, R., Tang, Q., Sun, S., Wu, R., Xu, S., Wang, M., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100926 · Cited by 26
Engineering biodegradable guanidyl-decorated PEG-PCL nanoparticles as robust exogenous activators of DCs and antigen cross-presentation
Li, P., Song, H., Zhang, H., Yang, P., Zhang, C., Huang, P., Kong, D., & Wang, W. (2017) · Nanoscale · doi:10.1039/c7nr04470d · Cited by 25
Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT
Sachpekidis, C., Anwar, H., Winkler, J. K., Kopp‐Schneider, A., Larribère, L., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2183-3 · Cited by 24
Reprogramming Tumor Associated Macrophage Phenotype by a Polysaccharide from Ilex asprella for Sarcoma Immunotherapy
Li, Q., Hao, Z., Hong, Y., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123816 · Cited by 25
Biomarker Discovery for Immunotherapy of Pituitary Adenomas: Enhanced Robustness and Prediction Ability by Modern Computational Tools
Yang, Q., Wang, Y., Zhang, S., Tang, J., Li, F., Yin, J., Li, Y., Fu, J., Li, B., Luo, Y., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010151 · Cited by 25
“With the advent of immunotherapy [40,41], the management of PA base for this new strategy has become the focus of current research [1,30].”
Background
Can CpG methylation serve as surrogate markers for immune infiltration in cancer?
Bacolod, M. D., Barany, F., & Fisher, P. B. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.007 · Cited by 25
Sources of inventive novelty: two patent classification schemas, same story
Lobo, J., & Strumsky, D. (2019) · Scientometrics · doi:10.1007/s11192-019-03102-2 · Cited by 25
“1 3 1 3 treatment (Couzin-Frankel 2013) and the patent for “immunopotentiative composition”, has been valued at $625 million dollars.7 Yet when using the patent’s USPC codes, the invention is classified as a refinement and when using the CPC codes, as a combination.”
Method
Rational design of anticancer platinum(IV) prodrugs
Zhang, S., Wang, X., & Guo, Z. (2019) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2019.10.009 · Cited by 25
Sustained Coevolution in a Stochastic Model of Cancer–Immune Interaction
George, J. T., & Levine, H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2732 · Cited by 23
Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors
Erhart, F., Hackl, M., Hahne, H., Buchroithner, J., Meng, C., Klingenbrunner, S., Reitermaier, R., Fischhuber, K., Skalicky, S., Berger, W., et al. (2020) · npj Vaccines · doi:10.1038/s41541-019-0149-x · Cited by 25
Linear support vector regression with linear constraints
Klopfenstein, Q., & Vaiter, S. (2021) · Machine Learning · doi:10.1007/s10994-021-06018-2 · Cited by 25

Authors: Couzin-Frankel, J.
Corresponding author: Couzin-Frankel, Jennifer
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-12-20
Volume: 342
Issue: 6165
Pages: 1432-1433
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.342.6165.1432
OpenAlex: W2209812019
Cited by: 2,051
References: 0
Citations by year: 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
FWCI: 73.49
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
MeSH terms: Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks